Bilateral Choroidal Osteoma Complicated by Bilateral Choroidal Neovascularization.
Angiogenesis Inhibitors
/ therapeutic use
Child
Choristoma
/ complications
Choroid Neoplasms
/ complications
Choroidal Neovascularization
/ drug therapy
Female
Humans
Osteoma
/ complications
Receptors, Vascular Endothelial Growth Factor
/ therapeutic use
Recombinant Fusion Proteins
/ therapeutic use
Treatment Outcome
Journal
Ophthalmic surgery, lasers & imaging retina
ISSN: 2325-8179
Titre abrégé: Ophthalmic Surg Lasers Imaging Retina
Pays: United States
ID NLM: 101599215
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
17
08
2018
accepted:
06
11
2018
entrez:
25
6
2019
pubmed:
25
6
2019
medline:
16
1
2020
Statut:
ppublish
Résumé
Choroidal osteoma is a rare, classically unilateral tumor. Less than half of the cases are complicated by the onset of choroidal neovascularization (CNV). The authors describe a case of bilateral choroidal osteoma in a 10-year-old female patient complicated by the onset of bilateral CNV. The diagnosis was made by multimodal imaging and ultrasonography. Best-corrected visual acuity (BCVA) was 20/63 for the right eye (OD) and 20/25 for the left eye (OS). Interestingly, CNV OD resulted exudative, whereas no signs of fluid were detected OS. OCT angiography (OCTA) clearly detected the presence of CNV in both eyes. The patient underwent a single 1.0 mg/0.025 mL aflibercept injection OD. At follow-up, BCVA improved to 20/32 OD after 1 month and to 20/25 after 3 months, with no exudation recurrence. Both BCVA and imaging findings were unremarkable OS, thus suggesting the possible "quiescent" nature of this CNV. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:398-400.].
Identifiants
pubmed: 31233159
doi: 10.3928/23258160-20190605-10
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
398-400Informations de copyright
Copyright 2019, SLACK Incorporated.